Med. pract. Stefanie Müller
Neurologie · Dept. III
Funktionelle Evaluation des autonomen Nervensystems im Zusammenhang mit der erstmaligen Einnahme von 0,5mg Fingolimod (Gilenya®) bei Patienten mit schubförmig verlaufender Multipler Sklerose
Aug 21, 20131.Synopsis 1.1.Hintergrund der Studie Multiple Sklerose (MS) ist eine chronische, demyelinisierende, immunvermittelte Erkrankung des zentralen Nervensystems, die durch Entzündung und Zerstörung von Axonen (Nervenzellbahnen) und Myelin (Isolierschicht...
Clinical Studies - Aug 21, 2013 - Jun 18, 2015
Completed
Project leader: Vehoff Jochen
Members: Müller Stefanie, Hundsberger Thomas
Swiss Multiple Sclerosis Cohort-Study (SMSC-Study): A Prospective Swiss wide Investigation of Key Phases in Disease Evolution and new Treatment options
Jan 1, 2013The key aims of the Swiss Multiple Sclerosis Cohort-Study (SMSC) are (1) To maintain a long-term cohort (>10 years) representative of the MS population currently living in Switzerland. This requires effective measures to limit drop-outs and the conti...
Clinical Studies - Jan 1, 2013 - Nov 30, 2022
Automatically Closed
Project leader: Müller Stefanie
Long-term, prospective, observational, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapy - FTY720
May 20, 2012Long-term, prospective, observational, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapy Study: FTY720 - 2403
Clinical Studies - May 20, 2012 - Dec 31, 2018
Automatically Closed
Project leader: Müller Stefanie
An observational study to assess persistence, adherence, quality of life, and treatment satisfaction in patients beginning therapy with the Avonex® PEN™
Apr 1, 2012An observational study to assess persistence, adherence, quality of life, and treatment satisfaction in patients beginning therapy with the Avonex® PEN™
Clinical Studies - Apr 1, 2012 - Apr 1, 2013
Completed
Project leader: Müller Stefanie
A 32-week, patient- and rater-blinded, randomized, multicenter, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from previous treatment with natalizumab to fingolimod (FTY720)
Apr 1, 2012A 32-week, patient- and rater-blinded, randomized, multicenter, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from previous treatment with natalizumab to fingolimod (FT...
Clinical Studies - Apr 1, 2012 - Dec 1, 2012
Aborted
Project leader: Müller Stefanie
Tenere Extension: A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis
May 1, 2011
Clinical Studies - May 1, 2011 - Dec 31, 2013
Completed
Project leader: Müller Stefanie
Members: Vehoff Jochen, Siebel Philip
A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis
Apr 1, 2011A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis Study: FTY720 - 2399
Clinical Studies - Apr 1, 2011 - Feb 28, 2012
Completed
Project leader: Müller Stefanie
Cohort Study comparing Corpus Callosum Atrophy as a marker of later development of cognitive impairment in patients with early and remitting relapsing multiple sclerosis
Mar 14, 2011Even in early stages of multiple sclerosis (MS), cognitive dysfunction is a leading cause of disability. It can have profound social and economic consequences for patients and their families. Cognitive impairment is affecting up to 65% of MS patients...
Clinical Studies - Mar 14, 2011 - May 31, 2011
Completed
Project leader: Yildiz Murat
Members: Vehoff Jochen, Müller Stefanie
Neurocognitive changes in patients with remitting relapsing multiple sclerosis treated with Natalizumab
Jan 1, 2011Neurocognitive changes in patients with remitting relapsing multiple sclerosis treated with Natalizumab
Clinical Studies - Jan 1, 2011 - Dec 31, 2012
Completed
Project leader: Yildiz Murat, Müller Stefanie
A dose blind, multicenter, extension study to determine the safety and efficasy of 2 doses of BG00012 monotherapy with Relapsin Remitting Multiple Sclerosis
Dec 1, 2010A dose blind, multicenter, extension study to determine the safety and efficasy of 2 doses of dimethyl fumarate (BG00012) monotherapy with Relapsin Remitting Multiple Sclerosis
Clinical Studies - Dec 1, 2010 - Dec 8, 2020
Automatically Closed
Project leader: Müller Stefanie
Members: Vehoff Jochen
A 4 Month, open label, multi-center study to explore the tolerability and safety and health outcomes of FTY720 in patients with relapsong forms of multiple sclerosis
Oct 1, 2010A 4 Month, open label, multi-center study to explore the tolerability and safety and health outcomes of FTY720 in patients with relapsong forms of multiple sclerosis Study: FTY720 - 2316
Clinical Studies - Oct 1, 2010 - May 31, 2011
Completed
Project leader: Müller Stefanie
Substudie zu SOLAR: Untersuchung der Wirkung einer Vitamin D-Substitution auf die T-Lymphozyten bei Patienten mit schubförmig-remittierender MS unter Beahndlung mit Rebif®, EMR 200136-532
Jul 1, 2010Substudie zu SOLAR: Untersuchung der Wirkung einer Vitamin D-Substitution auf die T-Lymphozyten bei Patienten mit schubförmig-remittierender MS unter Beahndlung mit Rebif®, EMR 200136-532
Clinical Studies - Jul 1, 2010 - Dec 31, 2013
Completed
Project leader: Müller Stefanie
Tenere: A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis
May 3, 2010Primary: To assess the effectiveness of 2 doses of teriflunomide in comparison to interferon-beta 1a, evaluated by the time to failure, with failure being defined as either relapse or permanent study treatment discontinuation for any cause whichever...
Clinical Studies - May 3, 2010 - Jun 30, 2011
Completed
Project leader: Putzki Norman
Members: Yildiz Murat, Siebel Philip, Vehoff Jochen, Coco Orazio, Müller Anna, Müller Stefanie
Selective S1P1 receptor agonist in Patients with Relapsing-Remitting Multiple Sclerosis
Nov 1, 2009Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding phase IIb study to evaluate the efficacy, safety, and tolerability of three doses of an oral S1P1 receptor agonist, administered for twenty-four weks in patients...
Clinical Studies - Nov 1, 2009 - Nov 1, 2010
Completed
Project leader: Putzki Norman
Members: Yildiz Murat, Müller Anna, Siebel Philip, Müller Stefanie
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of dimethyl fumarate (BG00012) in Subjects with Relapsing-Remitting Multiple Sclerosis
Oct 1, 2008Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of dimethyl fumarate in Subjects with Relapsing-Remitting Multiple Sclerosis primary objective: determine wether dimethyl fumarat...
Clinical Studies - Oct 1, 2008 - Dec 1, 2010
Completed
Project leader: Putzki Norman, Müller Stefanie
Members: Müller Anna, Yildiz Murat, Siebel Philip